Prediction of Gestational Diabetes Mellitus and Pre-diabetes 5 Years Postpartum using 75 g Oral Glucose Tolerance Test at 14–16 Weeks’ Gestation

Abstract Early detection and treatment of women at risk for gestational diabetes mellitus (GDM) could improve perinatal and long-term outcomes in GDM women and their offspring. We explored if a 75 g oral glucose tolerance test (OGTT) at 14–16 weeks of gestation could identify women who will (1) deve...

Full description

Bibliographic Details
Main Authors: Tove Lekva, Kristin Godang, Annika E. Michelsen, Elisabeth Qvigstad, Kjersti Ringvoll Normann, Errol R. Norwitz, Pål Aukrust, Tore Henriksen, Jens Bollerslev, Marie Cecilie Paasche Roland, Thor Ueland
Format: Article
Language:English
Published: Nature Publishing Group 2018-09-01
Series:Scientific Reports
Online Access:http://link.springer.com/article/10.1038/s41598-018-31614-z
id doaj-art-18a206ce67c44075a7298d470cfbb663
recordtype oai_dc
spelling doaj-art-18a206ce67c44075a7298d470cfbb6632018-09-09T12:16:16ZengNature Publishing GroupScientific Reports2045-23222018-09-01811910.1038/s41598-018-31614-zPrediction of Gestational Diabetes Mellitus and Pre-diabetes 5 Years Postpartum using 75 g Oral Glucose Tolerance Test at 14–16 Weeks’ GestationTove Lekva0Kristin Godang1Annika E. Michelsen2Elisabeth Qvigstad3Kjersti Ringvoll Normann4Errol R. Norwitz5Pål Aukrust6Tore Henriksen7Jens Bollerslev8Marie Cecilie Paasche Roland9Thor Ueland10Research Institute of Internal Medicine, Oslo University Hospital, RikshospitaletSection of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, RikshospitaletResearch Institute of Internal Medicine, Oslo University Hospital, RikshospitaletDepartment of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, AkerResearch Institute of Internal Medicine, Oslo University Hospital, RikshospitaletMother Infant Research Institute, Tufts Medical CenterResearch Institute of Internal Medicine, Oslo University Hospital, RikshospitaletFaculty of Medicine, University of OsloSection of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, RikshospitaletNational Advisory Unit for Womens Health, Oslo University Hospital, RikshospitaletResearch Institute of Internal Medicine, Oslo University Hospital, RikshospitaletAbstract Early detection and treatment of women at risk for gestational diabetes mellitus (GDM) could improve perinatal and long-term outcomes in GDM women and their offspring. We explored if a 75 g oral glucose tolerance test (OGTT) at 14–16 weeks of gestation could identify women who will (1) develop GDM or give birth to large-for-gestational-age (LGA) babies in 1031 pregnant women from the STORK study using different diagnostic criteria (WHO1999, IADPSG2010, WHO2013, NORWAY2017) and (2) develop pre-diabetes 5 years postpartum focusing on first trimester β-cell function in a separate study of 300 women from the STORK cohort. The sensitivity of the 14–16 week OGTT to identify women who would develop GDM or have LGA babies was low, and we could not identify alternative cut-offs to exclude women not at risk or identify women that could benefit from early intervention. First trimester β-cell function was a stronger determinant than third trimester β-cell function of predicting maternal pre-diabetes. In conclusion, in our normal low-risk population, the 75 g OGTT at 14–16 weeks is insufficient to identify candidates for early treatment of GDM or identify women not likely to develop GDM or have LGA babies. First trimester β-cell function may predict pre-diabetes 5 years postpartum.http://link.springer.com/article/10.1038/s41598-018-31614-z
institution Open Data Bank
collection Open Access Journals
building Directory of Open Access Journals
language English
format Article
author Tove Lekva
Kristin Godang
Annika E. Michelsen
Elisabeth Qvigstad
Kjersti Ringvoll Normann
Errol R. Norwitz
Pål Aukrust
Tore Henriksen
Jens Bollerslev
Marie Cecilie Paasche Roland
Thor Ueland
spellingShingle Tove Lekva
Kristin Godang
Annika E. Michelsen
Elisabeth Qvigstad
Kjersti Ringvoll Normann
Errol R. Norwitz
Pål Aukrust
Tore Henriksen
Jens Bollerslev
Marie Cecilie Paasche Roland
Thor Ueland
Prediction of Gestational Diabetes Mellitus and Pre-diabetes 5 Years Postpartum using 75 g Oral Glucose Tolerance Test at 14–16 Weeks’ Gestation
Scientific Reports
author_facet Tove Lekva
Kristin Godang
Annika E. Michelsen
Elisabeth Qvigstad
Kjersti Ringvoll Normann
Errol R. Norwitz
Pål Aukrust
Tore Henriksen
Jens Bollerslev
Marie Cecilie Paasche Roland
Thor Ueland
author_sort Tove Lekva
title Prediction of Gestational Diabetes Mellitus and Pre-diabetes 5 Years Postpartum using 75 g Oral Glucose Tolerance Test at 14–16 Weeks’ Gestation
title_short Prediction of Gestational Diabetes Mellitus and Pre-diabetes 5 Years Postpartum using 75 g Oral Glucose Tolerance Test at 14–16 Weeks’ Gestation
title_full Prediction of Gestational Diabetes Mellitus and Pre-diabetes 5 Years Postpartum using 75 g Oral Glucose Tolerance Test at 14–16 Weeks’ Gestation
title_fullStr Prediction of Gestational Diabetes Mellitus and Pre-diabetes 5 Years Postpartum using 75 g Oral Glucose Tolerance Test at 14–16 Weeks’ Gestation
title_full_unstemmed Prediction of Gestational Diabetes Mellitus and Pre-diabetes 5 Years Postpartum using 75 g Oral Glucose Tolerance Test at 14–16 Weeks’ Gestation
title_sort prediction of gestational diabetes mellitus and pre-diabetes 5 years postpartum using 75 g oral glucose tolerance test at 14–16 weeks’ gestation
publisher Nature Publishing Group
series Scientific Reports
issn 2045-2322
publishDate 2018-09-01
description Abstract Early detection and treatment of women at risk for gestational diabetes mellitus (GDM) could improve perinatal and long-term outcomes in GDM women and their offspring. We explored if a 75 g oral glucose tolerance test (OGTT) at 14–16 weeks of gestation could identify women who will (1) develop GDM or give birth to large-for-gestational-age (LGA) babies in 1031 pregnant women from the STORK study using different diagnostic criteria (WHO1999, IADPSG2010, WHO2013, NORWAY2017) and (2) develop pre-diabetes 5 years postpartum focusing on first trimester β-cell function in a separate study of 300 women from the STORK cohort. The sensitivity of the 14–16 week OGTT to identify women who would develop GDM or have LGA babies was low, and we could not identify alternative cut-offs to exclude women not at risk or identify women that could benefit from early intervention. First trimester β-cell function was a stronger determinant than third trimester β-cell function of predicting maternal pre-diabetes. In conclusion, in our normal low-risk population, the 75 g OGTT at 14–16 weeks is insufficient to identify candidates for early treatment of GDM or identify women not likely to develop GDM or have LGA babies. First trimester β-cell function may predict pre-diabetes 5 years postpartum.
url http://link.springer.com/article/10.1038/s41598-018-31614-z
_version_ 1612608166118293504